Immunotherapy is now considered a cornerstone of treatment for many forms of cancer, and its adoption has risen rapidly. As these treatments offer hope for patients in the form of longer and better-quality lives, as well as significant revenues for pharmaceuticals in the range of tens of billions of dollars, questions are arising about their broad use across types and stages of cancer.
VP Business Development, Payer Markets
George has over two decades of consulting, business development and client success experience in health care, working with both providers and payers to address their most pressing challenges. The bulk of his healthcare career was with The Advisory Board, Optum, Premier and Verisk Health, with a focus on risk mitigation, value-based care and population health management. He is deeply passionate about helping healthcare organizations do their best for their patients and beneficiaries.
When he’s not working, you will find him playing guitar, riding his bike or spending time with family, friends, and his dog Luna.